Imaging
and are the first nuclear imaging systems to break the sub-mm resolution barrier. Offering sub-mm PET and 10µm CT resolution, only the NanoPET/CT has the sensitivity and image quality to enable truly translational research. The new ‘Plus’ version of Bioscan’s popular NanoSPECT/CT enables users to reconstruct SPECT tomograms in real-time and supports both high-resolution (<350µm) stationary organ imaging and high- throughput whole-body helical scanning. This year, Bioscan will launch NanoFLECT, its groundbreak- ing fluorescence imaging system. NanoFLECT will be the first optical imaging system featuring true 360° tomography and optional inline X-Ray CT. In addition, Bioscan, together with a consortium of academic and commercial partners in Dijon, France, has been awarded more than €7 million by the French Government to develop a PET/MRI imaging system as well as associated animal models and consumables (Figure 12).
Caliper Life Sciences (
www.caliperls.com) is a lead- ing provider of innovative tools and services for preclinical life science research and drug discovery with leading edge optical technology, integrated x- ray and low dose microCT. It is steadily focused in supporting longitudinal experimental models while maintaining relevant biological settings, transla- tional applications and quantitative credibility. The optical imaging portfolio offers bioluminescence technology in both 2D and 3D with absolute quan- titative tools that enable researchers to detect dis- ease down to the number of cells. Caliper’s fluo-
Figure 12: Bioscan’s wide range multimodality imaging applications
rescence technology offers a wide range of tools to detect small amount of either cells or pmol levels of protein by means of spectral unmixing and nor- malise transmission fluorescence features. Moreover, Dynamic Contrast Imaging (DYCE) offers a translational approach to use either fluo- rescence or luminescence sources to quantify dynamic distribution of compounds in real time. Caliper’s recent introduction of the Quantum FX microCT has set a new standard in low dose
Figure 13 Caliper Life Sciences’
Quantum FX uCT scan with a nanoparticle contrast agent to visualise vasculature (left panel), and MB321 metastasis formation identified by 3D bioluminescence and co-registration with uCT (right panel)
Drug Discovery World Summer 2011
63
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92